Literature DB >> 23851020

Advanced imaging technologies increase detection of dysplasia and neoplasia in patients with Barrett's esophagus: a meta-analysis and systematic review.

Bashar J Qumseya1, Haibo Wang, Nicole Badie, Rosemary N Uzomba, Sravanthi Parasa, Donna L White, Herbert Wolfsen, Prateek Sharma, Michael B Wallace.   

Abstract

BACKGROUND & AIMS: US guidelines recommend surveillance of patients with Barrett's esophagus (BE) to detect dysplasia. BE conventionally is monitored via white-light endoscopy (WLE) and a collection of random biopsy specimens. However, this approach does not definitively or consistently detect areas of dysplasia. Advanced imaging technologies can increase the detection of dysplasia and cancer. We investigated whether these imaging technologies can increase the diagnostic yield for the detection of neoplasia in patients with BE, compared with WLE and analysis of random biopsy specimens.
METHODS: We performed a systematic review, using Medline and Embase, to identify relevant peer-review studies. Fourteen studies were included in the final analysis, with a total of 843 patients. Our metameter (estimate) of interest was the paired-risk difference (RD), defined as the difference in yield of the detection of dysplasia or cancer using advanced imaging vs WLE. The estimated paired-RD and 95% confidence interval (CI) were obtained using random-effects models. Heterogeneity was assessed by means of the Q statistic and the I(2) statistic. An exploratory meta-regression was performed to look for associations between the metameter and potential confounders or modifiers.
RESULTS: Overall, advanced imaging techniques increased the diagnostic yield for detection of dysplasia or cancer by 34% (95% CI, 20%-56%; P < .0001). A subgroup analysis showed that virtual chromoendoscopy significantly increased the diagnostic yield (RD, 0.34; 95% CI, 0.14-0.56; P < .0001). The RD for chromoendoscopy was 0.35 (95% CI, 0.13-0.56; P = .0001). There was no significant difference between virtual chromoendoscopy and chromoendoscopy, based on Student t test analysis (P = .45).
CONCLUSIONS: Based on a meta-analysis, advanced imaging techniques such as chromoendoscopy or virtual chromoendoscopy significantly increase the diagnostic yield for identification of dysplasia or cancer in patients with BE.
Copyright © 2013 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AI; Advanced Imaging; BE; Barrett’s Esophagus; Barrett’s esophagus; CBE; CE; CI; CLE; EAC; Esophageal Adenocarcinoma; FICE; Fujinon intelligent chromoendoscopy; NBI; PRISMA; QUADAS; Quality Assessment of Diagnostic Accuracy Studies; RB; RD; Risk Difference; VC; WLE; advanced imaging; chromoendoscopy; complete Barrett excision; confidence interval; confocal laser endomicroscopy; esophageal adenocarcinoma; narrow-band imaging; random biopsy; risk difference; virtual chromoendoscopy; white-light endoscopy

Mesh:

Year:  2013        PMID: 23851020      PMCID: PMC3910269          DOI: 10.1016/j.cgh.2013.06.017

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  39 in total

Review 1.  Epidemiologic trends in esophageal and gastric cancer in the United States.

Authors:  Linda Morris Brown; Susan S Devesa
Journal:  Surg Oncol Clin N Am       Date:  2002-04       Impact factor: 3.495

2.  Chromoendoscopy with methylene blue and associated DNA damage in Barrett's oesophagus.

Authors:  J R Olliver; C P Wild; P Sahay; S Dexter; L J Hardie
Journal:  Lancet       Date:  2003-08-02       Impact factor: 79.321

3.  The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years.

Authors:  D J Drewitz; R E Sampliner; H S Garewal
Journal:  Am J Gastroenterol       Date:  1997-02       Impact factor: 10.864

4.  Methylene blue-directed biopsies improve detection of intestinal metaplasia and dysplasia in Barrett's esophagus.

Authors:  M I Canto; S Setrakian; J Willis; A Chak; R Petras; N R Powe; M V Sivak
Journal:  Gastrointest Endosc       Date:  2000-05       Impact factor: 9.427

5.  Comparison of methylene blue-directed biopsies and conventional biopsies in the detection of intestinal metaplasia and dysplasia in Barrett's esophagus: a preliminary study.

Authors:  J M Wo; M B Ray; S Mayfield-Stokes; G Al-Sabbagh; F Gebrail; S P Slone; M A Wilson
Journal:  Gastrointest Endosc       Date:  2001-09       Impact factor: 9.427

6.  Autofluorescence endoscopy for detection of high-grade dysplasia in short-segment Barrett's esophagus.

Authors:  Klaudia Niepsuj; Grzegorz Niepsuj; Wojciech Cebula; Witold Zieleźnik; Mariusz Adamek; Andrzej Sielańczyk; Jakub Adamczyk; Józef Kurek; Aleksander Sieroń
Journal:  Gastrointest Endosc       Date:  2003-11       Impact factor: 9.427

7.  Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995.

Authors:  A Paloma Vizcaino; Victor Moreno; Rene Lambert; D Maxwell Parkin
Journal:  Int J Cancer       Date:  2002-06-20       Impact factor: 7.396

8.  An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus.

Authors:  D S Levine; R C Haggitt; P L Blount; P S Rabinovitch; V W Rusch; B J Reid
Journal:  Gastroenterology       Date:  1993-07       Impact factor: 22.682

9.  A randomized, prospective cross-over trial comparing methylene blue-directed biopsy and conventional random biopsy for detecting intestinal metaplasia and dysplasia in Barrett's esophagus.

Authors:  K Ragunath; N Krasner; V S Raman; M T Haqqani; W Y Cheung
Journal:  Endoscopy       Date:  2003-12       Impact factor: 10.093

10.  The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews.

Authors:  Penny Whiting; Anne W S Rutjes; Johannes B Reitsma; Patrick M M Bossuyt; Jos Kleijnen
Journal:  BMC Med Res Methodol       Date:  2003-11-10       Impact factor: 4.615

View more
  69 in total

Review 1.  Endoscopic options for early stage esophageal cancer.

Authors:  Pari M Shah; Hans Gerdes
Journal:  J Gastrointest Oncol       Date:  2015-02

Review 2.  Molecular markers and imaging tools to identify malignant potential in Barrett's esophagus.

Authors:  Michael Bennett; Hiroshi Mashimo
Journal:  World J Gastrointest Pathophysiol       Date:  2014-11-15

Review 3.  Chromoendoscopy: role in modern endoscopic imaging.

Authors:  Rajvinder Singh; Keng Hoong Chiam; Florencia Leiria; Leonardo Zorron Cheng Tao Pu; Kun Cheong Choi; Mariana Militz
Journal:  Transl Gastroenterol Hepatol       Date:  2020-07-05

4.  The Annual Risk of Esophageal Adenocarcinoma Does Not Decrease Over Time in Patients With Barrett's Esophagus.

Authors:  Theresa Nguyen; Aaron P Thrift; Xiaoying Yu; Zhigang Duan; Hashem B El-Serag
Journal:  Am J Gastroenterol       Date:  2017-02-28       Impact factor: 10.864

Review 5.  A guide to multimodal endoscopy imaging for gastrointestinal malignancy - an early indicator.

Authors:  Arthur Hoffman; Henrik Manner; Johannes W Rey; Ralf Kiesslich
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-06-14       Impact factor: 46.802

6.  Barrett's Esophagus With Low-Grade Dysplasia: Ablate or Wait?

Authors:  Sravanthi Parasa; Prateek Sharma
Journal:  Am J Gastroenterol       Date:  2017-01-17       Impact factor: 10.864

7.  Diagnostic and Management Implications of Basic Science Advances in Barrett's Esophagus.

Authors:  Meghan Jankowski; Sachin Wani
Journal:  Curr Treat Options Gastroenterol       Date:  2015-03

8.  Barrett's Esophagus.

Authors:  Shanmugarajah Rajendra; Prateek Sharma
Journal:  Curr Treat Options Gastroenterol       Date:  2014-06

Review 9.  Low grade dysplasia in Barrett's esophagus: Should we worry?

Authors:  Vamshi P Jagadesham; Clive J Kelty
Journal:  World J Gastrointest Pathophysiol       Date:  2014-05-15

10.  Efficacy Evaluation of SAVE for the Diagnosis of Superficial Neoplastic Lesion.

Authors:  Farah Deeba; Shahed K Mohammed; Francis Minhthang Bui; Khan A Wahid
Journal:  IEEE J Transl Eng Health Med       Date:  2017-05-04       Impact factor: 3.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.